Figure 1. Intratumoral phenotypic alterations in patients receiving epcoritamab-based therapies for B-NHL.

(a) Schematic and outcomes of patients treated in NCT04663347. (b) Immunohistochemistry of lymph node biopsies obtained from patients with FL at the timepoints indicated. (c) Dot plot depicting enrichment of MSigDB genesets in B-cell scRNA-seq transcriptomes from patients achieving a CR vs. PD as best response. (d) Differentially expressed genes in B-cells between patients who achieved a CR (right) vs. PD (left) as best response. P values calculated using Student’s t-test adjusted for multiple comparisons (d). FL, follicular lymphoma; DLBCL, diffuse large B-cell lymphoma; ND, newly diagnosed; RR, relapsed/refractory; CR, complete response; PD, progression of disease; H&E, hematoxylin and eosin; Epcor, epcoritamab; RCHOP, Rituximab, cyclophosphamide, vincristine, prednisone; GemOx, gemcitabine and oxaliplatin; Len, lenalidomide.